NASDAQ:ATRC
AtriCure Stock News
$31.94
-0.200 (-0.622%)
At Close: Mar 18, 2024
AtriCure, Inc. (ATRC) Q4 2023 Earnings Call Transcript
10:30pm, Thursday, 15'th Feb 2024
AtriCure, Inc. (ATRC) Q4 2023 Earnings Call Transcript
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings
08:01pm, Thursday, 15'th Feb 2024
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street esti
AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates
06:11pm, Thursday, 15'th Feb 2024
AtriCure (ATRC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.09 per share a year ago.
AtriCure: Appeal Lures For This Cure
02:59pm, Friday, 10'th Nov 2023
AtriCure has seen solid revenue growth but needs more operating leverage to improve its bottom line. The company's shares have experienced a meaningful pullback from their highs in June. Despite conti
All You Need to Know About AtriCure (ATRC) Rating Upgrade to Buy
01:32pm, Monday, 06'th Nov 2023
AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AtriCure, Inc. (ATRC) Q3 2023 Earnings Call Transcript
10:58pm, Wednesday, 01'st Nov 2023
AtriCure, Inc. (NASDAQ:ATRC ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Marissa Bych – Gilmartin Group, Investor Relations Mike Carrel – President and Chief
AtriCure (ATRC) Reports Q3 Earnings: What Key Metrics Have to Say
07:32pm, Wednesday, 01'st Nov 2023
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall St
AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
09:23pm, Tuesday, 25'th Jul 2023
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare t
AtriCure, Inc. (ATRC) Q2 2023 Earnings Call Transcript
07:40pm, Tuesday, 25'th Jul 2023
AtriCure, Inc. (NASDAQ:ATRC ) Q2 2023 Earnings Conference Call July 25, 2023 4:30 PM ET Company Participants Marissa Bych - Vice President-Gilmartin Group Mike Carrel - President & CEO Angie Wirick -
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
06:23pm, Tuesday, 25'th Jul 2023
AtriCure (ATRC) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.32 per share a year ago.
AtriCure to Participate at Upcoming Investor Conferences
08:00am, Friday, 21'st Jul 2023
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure to Announce Second Quarter 2023 Financial Results
08:00am, Monday, 03'rd Jul 2023
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure: Operating Leverage Is Required As A Cure
03:43pm, Wednesday, 14'th Jun 2023
AtriCure, Inc. has seen continued momentum in Afib and related markets. The company sees solid revenue growth, which, amidst a retreat in the share price, has resulted in rapidly narrowing sales multi
AtriCure, Inc. (ATRC) Q1 2023 Earnings Call Transcript
09:40pm, Tuesday, 02'nd May 2023
AtriCure, Inc. (NASDAQ:ATRC ) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Marissa Bych – Vice President-Gilmartin Group Mike Carrel – President and Chief Executive
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
07:09pm, Tuesday, 02'nd May 2023
AtriCure (ATRC) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.33 per share a year ago.